{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T18:20:04Z","timestamp":1792002004058,"version":"4.4.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.autrev.2021.102902","type":"journal-article","created":{"date-parts":[[2021,7,15]],"date-time":"2021-07-15T12:43:44Z","timestamp":1626353024000},"page":"102902","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"title":["JAK inhibitors and psoriatic arthritis: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"20","author":[{"given":"Francesco","family":"Campanaro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Batticciotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Zaffaroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Cappelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco Paolo","family":"Donadini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Squizzato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.autrev.2021.102902_bb0005","doi-asserted-by":"crossref","first-page":"65","DOI":"10.7861\/clinmedicine.17-1-65","article-title":"Psoriatic arthritis: state of the art review","volume":"17","author":"Coates","year":"2017","journal-title":"Clin Med (Lond)"},{"key":"10.1016\/j.autrev.2021.102902_bb0010","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.jaad.2015.05.001","article-title":"Prevalence of undiagnosed psoriatic arthritis among psoriasis patients: systematic review and meta-analysis","volume":"73","author":"Villani","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.autrev.2021.102902_bb0015","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.rdc.2015.07.001","article-title":"The epidemiology of psoriatic arthritis","volume":"41","author":"Ogdie","year":"2015","journal-title":"Rheum Dis Clin North Am"},{"issue":"6","key":"10.1016\/j.autrev.2021.102902_bb0020","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.autrev.2018.11.007","article-title":"Amplifying the concept of psoriatic arthritis: the role of autoimmunity in systemic psoriatic disease","volume":"18","author":"Chimenti","year":"2019","journal-title":"Autoimmun Rev"},{"issue":"8","key":"10.1016\/j.autrev.2021.102902_bb0025","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1080\/1744666X.2019.1627876","article-title":"An update on pathogenesis of psoriatic arthritis and potential therapeutic targets","volume":"5","author":"Chimenti","year":"2019","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.autrev.2021.102902_bb0030","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0049-0172(73)90035-8","article-title":"Psoriatic arthritis","volume":"3","author":"Moll","year":"1973","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.autrev.2021.102902_bb0035","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1002\/art.21972","article-title":"Classification criteria for psoriatic arthritis: development of new criteria from a large international study","volume":"54","author":"Taylor","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2021.102902_bb0040","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1097\/BOR.0000000000000152","article-title":"Recognizing and managing comorbidities in psoriatic arthritis","volume":"27","author":"Ogdie","year":"2015","journal-title":"Curr Opin Rheumatol"},{"issue":"3","key":"10.1016\/j.autrev.2021.102902_bb0045","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s10067-017-3975-0","article-title":"Metabolic syndrome in psoriatic arthritis: the interplay with cutaneous involvement. Evidence from literature and a recent cross-sectional study","volume":"37","author":"Caso","year":"2018","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2021.102902_bb0050","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1136\/annrheumdis-2020-217159","article-title":"EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update","volume":"79","author":"Gossec","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2021.102902_bb0055","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1136\/annrheumdis-2013-203419","article-title":"Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force","volume":"73","author":"Smolen","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.autrev.2021.102902_bb0060","doi-asserted-by":"crossref","first-page":"102731","DOI":"10.1016\/j.autrev.2020.102731","article-title":"Spondylitis-psoriasis-enthesitis-enterocolitis-dactylitis-uveitis-peripheral synovitis (SPEED-UP) treatment","volume":"20","author":"Br\u00fcner","year":"2021","journal-title":"Autoimmun Rev"},{"issue":"3","key":"10.1016\/j.autrev.2021.102902_bb0065","doi-asserted-by":"crossref","first-page":"102750","DOI":"10.1016\/j.autrev.2021.102750","article-title":"Working and safety profiles of JAK\/STAT signaling inhibitors. Are these small molecules also smart?","volume":"20","author":"Favoino","year":"2021","journal-title":"Autoimmun Rev"},{"issue":"Supplement_1","key":"10.1016\/j.autrev.2021.102902_bb0070","doi-asserted-by":"crossref","first-page":"i43","DOI":"10.1093\/rheumatology\/key276","article-title":"New players in the field of immune-mediated diseases, beyond rheumatoid arthritis","volume":"58","author":"Fragoulis","year":"2019","journal-title":"Rheumatology"},{"issue":"3","key":"10.1016\/j.autrev.2021.102902_bb0075","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2020-001374","article-title":"Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a systematic literature research","volume":"6","author":"Kerschbaumer","year":"2020","journal-title":"RMD Open"},{"key":"10.1016\/j.autrev.2021.102902_bb0080","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1056\/NEJMoa1615975","article-title":"Tofacitinib or adalimumab versus placebo for psoriatic arthritis","volume":"377","author":"Mease","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2021.102902_bb0085","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1056\/NEJMoa1615977","article-title":"Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors","volume":"377","author":"Gladman","year":"2017","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.autrev.2021.102902_bb0090","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1056\/NEJMoa2022516","article-title":"Trial of upadacitinib and adalimumab for psoriatic arthritis","volume":"384","author":"McInnes","year":"2021","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.autrev.2021.102902_bb0095","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1136\/annrheumdis-2020-218870","article-title":"Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2","volume":"80","author":"Mease","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2021.102902_bb0100","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1016\/S0140-6736(18)32483-8","article-title":"Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial","volume":"392","author":"Mease","year":"2018","journal-title":"Lancet."},{"issue":"11","key":"10.1016\/j.autrev.2021.102902_bb0110","doi-asserted-by":"crossref","first-page":"102390","DOI":"10.1016\/j.autrev.2019.102390","article-title":"JAK inhibitors for the treatment of autoimmune and inflammatory diseases","volume":"18","author":"Jamilloux","year":"2019","journal-title":"Autoimmun Rev"},{"issue":"4","key":"10.1016\/j.autrev.2021.102902_bb0115","doi-asserted-by":"crossref","first-page":"W65","DOI":"10.7326\/0003-4819-151-4-200908180-00136","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"151","author":"Liberati","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.autrev.2021.102902_bb0120","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/art.1780380602","article-title":"American College of Rheumatology: preliminary definition of improvement in rheumatoid arthritis","volume":"38","author":"Felson","year":"1995","journal-title":"Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.autrev.2021.102902_bb0125","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1002\/1529-0131(199809)41:9<1564::AID-ART6>3.0.CO;2-M","article-title":"Should improvement in rheumatoid arthritis clinical trials be defined as fifty percent or seventy percent improvement in core set measures, rather than twenty percent?","volume":"41","author":"Felson","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2021.102902_bb0135","first-page":"1401","article-title":"Standardizing assessment and reporting of adverse effects in rheumatology clinical trials II: the Rheumatology Common Toxicity Criteria v.2.0","volume":"34","author":"Woodworth","year":"2007","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2021.102902_bb0140","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ."},{"key":"10.1016\/j.autrev.2021.102902_bb0145","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"issue":"8","key":"10.1016\/j.autrev.2021.102902_bb0150","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1111\/1346-8138.13258","article-title":"Oral tofacitinib efficacy, safety and tolerability in Japanese patients with moderate to severe plaque psoriasis and psoriatic arthritis: a randomized, double-blind, phase 3 study","volume":"43","author":"Asahina","year":"2016","journal-title":"J Dermatol"},{"issue":"6","key":"10.1016\/j.autrev.2021.102902_bb0155","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.autrev.2018.12.009","article-title":"Systemic rheumatic diseases: from biological agents to small molecules","volume":"18","author":"Sarzi-Puttini","year":"2019","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2021.102902_bb0160","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/art.39573","article-title":"Group for Research and Assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritis","volume":"68","author":"Coates","year":"2016","journal-title":"Arthritis Rheumatol"},{"issue":"10012","key":"10.1016\/j.autrev.2021.102902_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(15)00347-5","article-title":"Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial","volume":"386","author":"Coates","year":"2015","journal-title":"Lancet."},{"key":"10.1016\/j.autrev.2021.102902_bb0170","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1136\/annrheumdis-2016-210322","article-title":"Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study","volume":"76","author":"van der Heijde","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2021.102902_bb0175","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1016\/S0140-6736(18)32463-2","article-title":"Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial","volume":"392","author":"van der Heijde","year":"2018","journal-title":"Lancet."},{"key":"10.1016\/j.autrev.2021.102902_bb0180","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1016\/S0140-6736(19)32534-6","article-title":"Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2\/3 trial","volume":"394","author":"van der Heijde","year":"2019","journal-title":"Lancet."}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997221001750?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997221001750?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:24:13Z","timestamp":1761600253000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997221001750"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":34,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S1568997221001750"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2021.102902","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"JAK inhibitors and psoriatic arthritis: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2021.102902","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102902"}}